Melphalan flufenamide (Pepaxto; Oncopeptides AB) in combination with dexamethasone was granted accelerated approval on February 26, 2021, by the FDA for adult patients with relapsed or refractory multiple myeloma.
Samantha Troy, 2021 PharmD candidate
Advertisement
Samantha Troy is a 2021 PharmD candidate at the University of Connecticut School of Pharmacy in Storrs.
Articles by Samantha Troy, 2021 PharmD candidate
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
2
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
3
Investigational Oral AD109 Reduces Sleep Apnea Severity by 44%
4
Zepbound Lowers Health Care Costs in Older Adults With Obesity
5